________________________________________________________________________________ >48cc group was 90% vs 46% (chi square p =.001). ROC curve analysis of our oropharyngeal subgroup revealed similar results with a cut off of 48cc with AUC of 0.802 (0.677-0.927) and sensitivity / specificity of 86%/70%.The RR for the <48cc and >48cc group was 88% vs 40% (chi square p = .001). The likelihood of not responding increased by 1.8%% for 1cc increase in TTV for the entire cohort and by 2.4% for our oropharyngeal subgroup.
Purpose or Objective: To evaluate the prognostic value of 18F-FDG PET-CT performed prior to (prePET) and during the third week (iPET) of radiation therapy (RT) in patients with newly diagnosed nasopharyngeal carcinoma (NPC).
Material and Methods:
Thirty patients with newly diagnosed NPC treated with radical RT and Cisplatin-based chemotherapy underwent prePET and iPET. The median follow up was 26 months (range 8-66.9). AJCC staging included 12 patients in stage II, 8 in stage III and 10 in stage IV. The maximum standardised-uptake-value (SUVmax), metabolic-tumour-volume (MTV) and total-lesional-glycolysis (TLG) of primary tumour (PT), the index-node (IN) (defined as lymph node with highest TLG), total lymph nodes (TN) and combined primary tumour and nodal (PTN), and their % reductions in iPET were analysed, and results were correlated with 2-year loco-recurrence-free-survival (LRFS), regionalfailure-free-survival (RFFS), distant-metastatic-failure-freesurvival (DMFFS), disease-free-survival (DFS), and overallsurvival (OS), using Kaplan-Meier (KM) analysis. Optimalcutoffs (OC) were derived from Receiver-OperatingCharacteristic curves for the best combined sensitivity and specificity.
Results: For LRFS, the only statistically significant predictor was reduction in primary tumour MTV by >50% in iPET (95.2% vs 75.0%, p= 0.024). For other treatment outcomes, only nodal or combined PTN predicted treatment outcomes. The IN SUVmax (pre-PET OC= 10.45g/mL and iPET OC= 8.15g/mL) and TLG (pre-PET OC= 90g and iPET OC= 33.4g) provide the overall best predictor of outcome, with significant associations with RFFS (iPET only), DMFFS (prePET), DFS (prePET and iPET) and OS (prePET) 
Conclusion:
The metabolic parameters of prePET and iPET can provide complementary prognostic biomarkers of patient outcomes, These parameters may have a role in adaptive therapy for NPC, and identifying the best treatment strategy for precision individualised chemo-radiotherapy combinations. We have demonstrated IN to be a useful novel imaging biomarker for predicting all treatment outcomes, and offers additional potential advantage of ease of generation and reproducibility compared to TN or PTN. 
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Material and Methods:
We identified 83 consecutive patients with laryngeal squamous cell carcinoma treated with definitive RT with available pretreatment PET/CT scans at our institution. Clinical variables related to disease and patient characteristics, treatment information, and clinical outcomes data were collected for each patient. Pretreatment PET/CT scans were used for image feature analysis of the primary tumor volume for each patient. Multiple statistical image features were computed, along with several measures related to the standardized uptake value (SUV). Redundant image features were excluded based on a strong correlation with parameters commonly reported as important such as metabolic tumor volume (MTV) and maximum SUV value (SUVmax). A LASSO procedure was applied to select appropriate variables to include in Cox proportional hazard models for local control (LC) progression-free survival (PFS) and overall survival (OS). The concordance index or "Cindex" was computed to evaluate the discriminative ability of each model, both on the training data set (apparent C-index) and using bootstrap cross-validation (bCV). Correction for
